Daiichi Sankyo has formed a new consortium focused on research and discovery of medicines over a period of five years to treat intractable immune-mediated inflammatory diseases.

The Immune-mediated Inflammatory Diseases Consortium for Drug Development has been launched in alliance with other Japanese pharmaceutical organisations and companies, such as Keio University, Ono Pharmaceutical, the National Institutes of Biomedical Innovation, Health and Nutrition and Mitsubishi Tanabe Pharma.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

While scientists are conducting reverse translational research globally to find new drugs for intractable immune-mediated inflammatory conditions, the volume of clinical samples from these patients is limited and costs are high.

Daiichi Sankyo noted that the new partnership with various academia and industry members is intended to address these challenges to efficient drug discovery.

“The new partnership with various academia and industry members is intended to address challenges to efficient drug discovery.”

Keio University Hospital and Kochi University will be responsible for the collection of clinical samples and detailed information before as well as after the treatment of patients.

The National Institutes of Biomedical Innovation, Health and Nutrition will carry out detailed and comprehensive analysis, including transcriptome analysis, on the obtained samples.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A database of different data types will be assembled by the consortium and shared with the participating academic institutions and pharmaceutical companies.

Each company will then use the database to perform original drug discovery research for these conditions, while the academia members will leverage findings from the study to advance basic and applied research.

Daiichi Sankyo considers the intractable and rare diseases as difficult-to-cure cases with the use of existing standards and wants to provide new treatment options through the continuous creation of advanced pharmaceuticals.